Logo image
Liver Cancer–Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma
Journal article   Open access   Peer reviewed

Liver Cancer–Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma

Felix Lu, Pir Ahmad Shah, Abhishek Rao, Cynthia Gifford-Hollingsworth, Anne Chen, Gary Trey, Mina Soryal, Arslan Talat, Aysha Aslam, Bilal Nasir, …
Clinical and translational gastroenterology, v 11(12), pp e00271-e00271
23 Nov 2020
PMID: 33512798
url
https://doi.org/10.14309/ctg.0000000000000271View
Published, Version of Record (VoR)CC BY-NC-ND V4.0 Open

Abstract

Liver
Liver cancer–secreted serine protease inhibitor Kazal (LC-SPIK) is a protein that is specifically elevated in cases of hepatocellular carcinoma (HCC). We assessed the performance of LC-SPIK in detecting HCC, including its early stages, in patients with cirrhosis, hepatitis B virus (HBV), and hepatitis C virus (HCV).

Metrics

11 Record Views
12 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Gastroenterology & Hepatology
Logo image